Propel Bio Management, LLC Kymera Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $101 Billion
- Q4 2024
A detailed history of Propel Bio Management, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 56,359 shares of KYMR stock, worth $1.85 Million. This represents 2.25% of its overall portfolio holdings.
Number of Shares
56,359
Previous 56,359
-0.0%
Holding current value
$1.85 Million
Previous $2.67 Billion
15.0%
% of portfolio
2.25%
Previous 1.55%
Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
186Shares Held
65.6MCall Options Held
49.6KPut Options Held
17K-
Price T Rowe Associates Inc Baltimore, MD6.87MShares$226 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$197 Million2.67% of portfolio
-
Wellington Management Group LLP Boston, MA5.31MShares$175 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$170 Million7.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.15MShares$169 Million3.02% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.8B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...